Vorhabensbeschreibung zu Sp 3 / TP 3

Teilprojektleiter

Prof. Dr. med. Christoph Röcken

 


Klassifikation der systemischen Amyloidosen durch Gewebsuntersuchungen mittels MALDI im Amyloid Register Kiel

Ziele des Teilprojekts ist es, die Klassifikation systemischer Amyloidosen durch den Einsatz von Tissue MALDI Imaging an Formalin-fixierten und in Paraffin eingebetteten Gewebeproben zu verbessern. Der Nutzen des Tissue MALDI Imagings für die Evaluation des Therapieansprechens soll geprüft werden. Ein Pathologie Referenzzentrum für das GERAMY Konsortium soll vorgehalten werden.

 


Classification of systemic amyloidosis by tissue MALDI imaging

The treatment of amyloidosis depends on the type of amyloid present in the patient and therefore classification of amyloid is of paramount importance for patient management.
Currently, the most serious problem is to distinguish immunoglobulin-derived AL amyloidosis from rare hereditary type amyloidoses. The former necessitates chemotherapy, the latter genetic counselling and possibly organ transplantation.
One central aim of this project is to improve classification of systemic amyloidosis by using tissue matrix-assisted laser desorption/ionisation (MALDI) imaging. The MALDI technique shall also be applied to evaluate the effect of epigallocatechin-3-gallate (EGCG) on amyloid regression within the clinical trial (SP1).
The subproject further provides a central surgical pathology unit to the consortium. The unit collects and provides tissue samples from the Amyloid Registry Kiel and samples sent in from the Amyloidosis Clinic Heidelberg. The unit sends out surgical pathology reports for specimens provided by the consortium in order to facilitate adequate patient management and treatment. It will house and coordinate the central tissue and histology database (Amyloid Registry Kiel).